Skip to main content
All lobbying filings

Holland & Knight LLP

Holland & Knight LLP filed a Q1 report for Convatec, Inc. F/K/A Triad Life Sciences, Inc. on April 17, 2026, reporting $90,000 in lobbying income.

Lobbying for Convatec, Inc. F/K/A Triad Life Sciences, Inc. · Biotechnology

As filed: HOLLAND & KNIGHT LLP for CONVATEC, INC. F/K/A TRIAD LIFE SCIENCES, INC.

All filings by Holland & Knight LLP · Everything Convatec, Inc. F/K/A Triad Life Sciences, Inc. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Income
$90,000
What the client paid this registrant for the period.
Client based in
Tennessee

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

S. 2561 / H.R. 5768 - Medicare coverage of wound care therapies; Skin Substitute Access & Payment Reform Act; H.R. 6852 - Advanced Wound Care and Regenerative Medicine Access and Reform Act; competitive bidding.

 Bills named in this filing 3
  • S. 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • H.R. 5768
    Skin Substitute Access and Payment Reform Act
  • H.R. 6852
    Advanced Wound Care and Regenerative Medicine Access and Reform Act
 Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • CONVATEC GROUP PLC.
    United Kingdom · Paddington, London · owns 100% of the client · contributed $0

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem